About 300-400 genes among the 20,000 human genes are related to cancer, and cancer is caused by germline or somatic mutations in those cancer-related genes. For example, if a gene controlling growth is mutated, the genetically altered cell may start to abnormally proliferate and cause the formation of a tumor. Patients with different cancer types may have the same genetic alterations .
Through the ever advancing progress of medicine, it is now known that using certain treatment strategies can have a more significant treatment effect for patients with specific genetic mutations. Precision medicine can surpass current treatment plans that are only based on cancer types and instead utilizes genetic testing to identify the mutated genes and provide precise treatment strategies. Thus, cancer can be managed more efficiently, avoiding unnecessary side effects and empowering physicians and patients to gain valuable time.
An approach that can yield a better outcome is a personalized treatment tailored for your individual cancer. Researchers and physicians have discovered that there is a strong association between the genomic alterations of a patient’s tumor and the success of using tailored targeted therapies. More and more of these targeted therapies are used in the clinic with impressive success, and are prescribed based on a patient’s tumor genomic alterations. Those therapies are already commonly used for some cancer types, such as for lung cancer. However, patients with a wide variety of cancer types can find a suitable targeted treatment through tumor genomic testing. By performing comprehensive genomic testing, ACT Genomics provides you with the most promising tailored treatment options to help you fight your cancer.
Act now and manage your cancer from cancer prevention, cancer treatment, cancer monitoring and immunotherapy evaluation through genomic testing.
Have I inherited mutations of cancer-related genes?
There are 5%-10% hereditary cancer among all, and the most common hereditary cancers are breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer and kidney cancer. Hereditary cancers are caused by mutations in cancer-related genes. Many of those genes help repair damaged DNA, and if these genes do not function correctly, further genetic alterations may develop and cause cancer. Examples for such genes are BRCA1/2, and BRCA1/2 mutations increases the risk of developing breast cancer, ovarian cancer, prostate cancer and pancreatic cancer. If your family members have cancer types with a high risk of a hereditary cause, you may consider using our cancer genetic testing to find out if you have inherited mutations in cancer-related genes and start to take actions for cancer prevention and early detection.
If you would like to know if you have inherited mutations in cancer-related genes, you may consider using our risk assessment service: ACTRisk™
Why do I need genetic testing to treat my cancer?
The latest cancer treatment perspective is Precision Medicine. Using cancer genomic testing to treat cancer provides a breakthrough in current cancer type-based treatment strategies, and identifies more appropriate treatment options according to the cancer’s genomic mutation profile. According to the World Cancer Foundation, the most common cancers worldwide in 2012 were lung cancer, breast cancer, colorectal cancer and prostate cancer. Patients with different cancer types may harbor the same genetic mutations, while different genetic mutations may occur in patients of the same cancer type. For this reason, effective treatment strategies may be used cross various cancer types, and genetic mutation-based treatment plans are very precise. For example, genomic testing can identify breast cancer patients who are likely to benefit from drugs approved for prostate cancer. Cancer genomic profiles may be complicated and new mutations may emerge fast. Comprehensive cancer genomic profiling services analyze the cancer genomic profile to provide more effective treatment options and guide clinical decisions even in patients with drug resistance, relapse and metastasis.
If you would like to have a comprehensive evaluation of immunotherapy, targeted therapy, hormone therapy and chemotherapy choices, you may consider using our comprehensive genomic profiling service: ACTOnco®+
If you would like to have an evaluation of targeted therapy choices, you may consider using our target genomic profiling service: ACTDrug®+
If you would like to have a treatment evaluation for specific dugs, you may consider using our BRCA1/2 test ACTBRCA™
How do I monitor my cancer after treatment?
Cancer needs to be monitored in different periods for different purposes, such as to detect if the tumor is totally removed after a surgery, check if the tumor is shrinking or becoming bigger, monitor drug resistance, and prevent cancer recurrence. Traditional ways to monitor cancer includes using blood tests to check the tumor proteins levels, such as the carcinoembryonic antigen (CEA) test, and conducting radio imaging examination such as regular chest x-rays and CT scans. A new cancer monitoring technology is to use liquid biopsy to directly detect circulating tumor DNA, ctDNA in the blood. ctDNA can indicate tumor dynamics before it can be observed by traditional methods. Monitoring ctDNA through genomic testing can detect genetic mutations correlated with drug resistance, provide assessment on treatment responses and early detection for cancer recurrence. Our ACTMonitor™ genomic testing can help you to track treatment results, increase treatment effectiveness, and detect cancer recurrence .
If you would like to monitor your treatment more effectively, you may consider using our cancer monitoring service, ACTMonitor ™
Do I benefit from Immunotherapy?
Immunotherapy is a type of cancer treatment that helps your immune system to fight cancer. Immune checkpoint inhibitors are drugs that can help T-cells to recognize and attack cancer cells. However, without immunotherapy-specific analysis, only 20% to 30% of patients are likely to benefit from immune checkpoint inhibitors, their efficacy varies among different tumor types and depends on genomic alternations in cancer cells.
Therefore, it is critical to have an accurate method to predict the response to these drugs. To evaluate if you are likely to benefit from therapy with immune checkpoint inhibitors, you may consider using our immunotherapy prediction genomic test ACTOnco™.
|Service||Why? (Purpose)||Who? (Design for)||What? (Tested Gene)||When? (Turnaround Time)||How?(Sample Requirement)|
|Preventive screening and detects inherited driver mutations||Sequencing 32 hereditary cancer related genes||30 Calendar days|
|Analyzing BRCA1/2 exons and detects somatic and germline mutations||Sequencing of all BRCA1/2 exons||14 Calendar days|
|Comprehensive genomic profile and recommendations of targeted drugs||Comprehensive profiling genomic profiling for 440 cancer-related genes||14 Calendar days|
|Providing tailored drug options||Genomic profiling for 35 druggable genes||14 Calendar days|
|Monitoring of cancer recurrence and drug resistance||Sequencing from 8-50 genes (optionable panels for specific cancer types)||14 Calendar days||Whole blood (Plasma)|